Do Preclinical Testing Strategies Help Predict Human Hepatotoxic Potentials?

Toxicologic Pathology - Tập 33 Số 1 - Trang 146-154 - 2005
Terry Peters1
1Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Rockville, Maryland, USA

Tóm tắt

Overt hepatotoxicity due to drug administration is a real and present issue in drug development and regulatory circles. Preclinical drug development is intended to identify potential risks and target tissues prior to introduction of new molecular entities into the human population. The standard regimen is testing at various multiples of the intended human therapeutic dose in at least 2 species of animals, one rodent (rats or mice), one non-rodent (dogs, nonhuman primates, minipigs, and rabbits, as examples) for at least two weeks of repeated dosing. Experience has shown that this regimen “works” most of the time. However, preclinical models are not infallible and are not always predictive. Whether the lack of predictivity is due to individual human genetic sensitivities, immunologically mediated phenomena, disease mediation or idiosyncratic reactions, the animal models are limited in detecting these characteristics and other low incidence phenomena. While it is uncommon for drug developers to continue development with products that elicit overt hepatic toxicity early in the animal testing, some products have made it through the approval process and then shown significant adverse effects. Some of the drugs (acetaminophen, isoniazid, trovafloxacin, troglitazone, bromfenac, clarithromycin, telithromycin) that have shown this propensity will be discussed in detail from early preclinical development to marketing and, in some instances, to limitations to usage or removal from the U.S. marketplace.

Từ khóa


Tài liệu tham khảo

Alden C, 2003, Preclinica, 27

10.1016/0168-8278(90)90124-A

10.1080/15376510309824

Boelsterli UA, 2003, Curr Opin Drug Disc Deliv, 6, 81

10.1055/s-2002-30102

10.1055/s-2002-30102

Cohen SD, 1998, Toxicology of the Liver, 159

10.1016/S0025-7125(05)70309-6

Eaton DL, 1996, Casarett and Doull’s Toxicology: The Basic Science of Poisons, 5, 13

10.1002/lt.500050607

10.1016/S1089-3261(02)00011-9

Greaves P, 2004, Nature, 3, 226

Gurumuthy P, 1984, Am Rev Respir Dis, 129, 58

Kaplowitz N, 2001, Drug Safety 2001, 24, 483

Karthikeyan S, 2002, Biomedicine, 22, 69

10.1021/tx000180q

10.1016/S0300-483X(02)00692-3

Kleiner DE, 1997, Mod Path, 10, 192

10.1177/096032718500400202

10.1055/s-2003-42641

10.1016/S0009-2797(02)00051-0

10.1177/009286150303700204

10.1053/gast.2000.9365

10.1006/rtph.2000.1399

10.7326/0003-4819-137-12-200212170-00007

10.1016/S0300-483X(00)00303-6

10.1124/jpet.102.041624

Scheen AJ, 2001, Drug Safety 2001, 24, 873

Scheen AJ, 2001, Diabetes Metab, 27, 305

10.1345/aph.1A038

10.1517/13543784.12.7.1179

Szela GA, 2003, Gastroenterologia Polska, 10, 424

10.1002/hep.510280124

10.1016/S1089-3261(03)00021-7

Tolman KG, 2000, Int Jrnl of Clin Practice, 113, 29

10.1054/cdip.2003.0162

10.2174/1389200003339081

10.1016/0732-8893(93)90112-K

Weber WW, Fed Proc, 42, 3086

10.1164/rccm.200206-626OC

10.1093/clinids/18.6.1025

10.1016/S1089-3261(05)70097-0

Thông tin
Thông tin xuất bản

Toxicologic Pathology

Tập 33 Số 1

146-154

Thông tin tác giả